Solabia announces the acquisition of the botanicals and in vitro diagnostics business of Seqens, reinforcing its position in the cosmetics ingredients market.
Solabia recently acquired Seqens« botanical actives and in vitro diagnostics (»IVD") business, a move which will enable the company to develop active plant ingredients for cosmetics, as well as plasmas and serums for diagnostic applications. The production site, located in Limoges, is renowned for its expertise in botanical extraction and high-end manufacturing. Solabia sees this acquisition as a strategic opportunity to strengthen its product portfolio and secure essential supplies for its diagnostics activities.
A natural addition to the group
Jean-Baptiste Dellon, CEO of Solabia, said: « We are delighted to welcome Seqens' Actifs Botaniques and IVD teams to Solabia. Because we operate in common activities, this acquisition is a natural and highly complementary development. By combining our capabilities, we will strengthen our market position, secure key supply chains and offer our customers even more robust and innovative solutions. "
This integration is designed to foster the development of innovative solutions in the cosmetics and diagnostics segments, sectors in which Solabia is already committed to sustainable growth.
Evolving with a long-term vision
Pascal Villemagne, CEO of Seqens, added: « This operation is fully in line with our long-term strategic vision. It will enable Seqens to focus more on its key priorities, while ensuring that the Limoges teams join a group whose industrial and scientific culture is strongly aligned with their activities. »This partnership is presented as a key step in the ongoing development of skills and know-how at the Limoges site. The market for cosmetic ingredients continues to evolve, and players like Solabia are striving to meet the growing demands for innovation and sustainability for the benefit of their customers.
